ERBB2 and breast carcinoma: Two breast cancer cell lines, representative of ER + (MCF7) and HER2 + (SKBR3) breast cancers, as well as a non-tumorigenic cell line (MCF10A), were subjected to tandem mass spectrometric analysis to enable proteome-level detection of altered peptide sequences.